Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue
+1.44%
EPS
−21.6%
Free cash flow
−25.3%
Total debt
+3.04%

Quarter to September 2026, against a year earlier

42.90 1.74 −3.90%
Market cap
$64.7B
P/E
18.7×
Fwd P/E
17.0×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a

Boston Scientific Corporation 8-K filed Jan 31, 2024

Period ended Jan 31, 2024 · Filed · accepted 6:32 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release